Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Covigenix VAX-001 COVID-19 Vaccine in Healthy Adults
NCT04591184Phase 2Completed
- Sponsor
- Entos Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of Covigenix VAX-001 in coronavirus disease 2019 (COVID-19), sponsored by Entos Pharmaceuticals. Started Apr 2021; status: completed.
02
Drugs
Covigenix VAX-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04591184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591184.